Recent large-scale studies involving nearly two million patients with type 2 diabetes or obesity have found no evidence that semaglutide, marketed as Ozempic and Wegovy, increases the risk of suicidal thoughts1 . In fact, these medications were associated with a reduced risk of both new and recurrent suicidal ideation compared to other anti-obesity and anti-diabetes drugs1 . This finding offers reassurance about the psychiatric safety of these widely used treatments2 .
Comparing Ozempic and Wegovy with Other Drugs
Semaglutide, the active ingredient in Ozempic and Wegovy, belongs to a class of medications called glucagon-like peptide-1 receptor (GLP-1R) agonists. These drugs are prescribed for type 2 diabetes and obesity and work by mimicking hormones that regulate appetite and blood sugar3 . Regulatory agencies such as the European Medicines Agency (EMA) have reviewed GLP-1R agonists for psychiatric adverse events, including suicidal ideation, prompting extensive research into their safety profiles4 56.
Large observational cohort studies using electronic health records have provided robust comparative safety data on semaglutide versus other anti-obesity and anti-diabetes medications5 7. These studies typically use propensity score matching to control for confounding factors such as age, sex, ethnicity, and prior psychiatric history5 7. For example, Wang et al. analyzed over 240,000 patients prescribed semaglutide or other weight loss drugs and over 1.5 million patients with type 2 diabetes, finding that semaglutide users had significantly lower risks of suicidal ideation8 9.
Key findings from these comparative studies include:
- Semaglutide was associated with a 49% to 73% lower risk of first-time or recurrent suicidal ideations compared to other medications for obesity and type 2 diabetes2 .
- Among people without prior suicidal thoughts, only 0.11% of semaglutide users reported suicidal ideation within six months, compared to 0.43% of those on other anti-obesity drugs3 .
- In patients with a history of suicidal ideation, 6.5% of semaglutide users reported recurrent suicidal thoughts versus 14.1% for other drugs3 .
- The reduced risk associated with semaglutide was consistent across demographic groups, including age, sex, and ethnicity, and persisted for up to three years of follow-up5 73.
| Medication Group | First-time Suicidal Ideation Risk | Recurrent Suicidal Ideation Risk |
|---|---|---|
| Semaglutide (Obesity) | 0.11% 3 | 6.5% 3 |
| Other Anti-Obesity Drugs | 0.43% 3 | 14.1% 3 |
| Semaglutide (Type 2 Diabetes) | 0.13% 3 | 10% 3 |
| Other Diabetes Drugs | 0.36% 3 | 18% 3 |
These findings do not support anecdotal reports suggesting increased suicidal thoughts as a side effect of semaglutide3 . The FDA has also reviewed adverse event reports and clinical trial data, concluding that there is no clear relationship between GLP-1R agonist use and suicidal thoughts or actions, although continued monitoring is advised10 .
Weight Loss Drugs, Diabetes Medications, and Suicidal Thoughts
The relationship between obesity, type 2 diabetes, and suicidal ideation is complex and influenced by multiple factors beyond medication effects. While obesity has been linked to increased risk of suicidal thoughts in some studies, other research has found no direct association in certain populations, such as young adults11 12. Weight discrimination, however, is a significant risk factor for suicidal ideation among individuals with obesity13 14.
Type 2 diabetes is more consistently associated with higher rates of depression and suicidal behavior, likely due to the chronic disease burden rather than specific drug effects5 7. Previous weight loss drugs have been withdrawn from the market due to increased risk of suicidal ideation, which has led to heightened scrutiny of newer agents like GLP-1R agonists15 164.
From a social identity perspective, GLP-1 medications could even be perceived as a tool to eradicate an entire social group—those that identify as higher weight18 .
The mechanisms behind semaglutide's association with a lower risk of suicidal ideation are not fully understood. It may involve the drug’s effects on brain regions responsible for emotional regulation and neurotransmitter systems17 5. However, some research has reported mixed mental health effects of GLP-1 drugs, including cases of increased anxiety, depression, or suicidal behavior in people with pre-existing psychiatric conditions or genetic predispositions18 . Conversely, other studies found no increased risk of depression or suicidal thoughts in patients without known psychopathology and even observed small improvements in depressive symptoms18 .
Key points regarding the interplay of weight loss, diabetes medications, and suicidal ideation include:
- Suicidality in patients with obesity or type 2 diabetes is more likely related to the chronic disease burden than to GLP-1 receptor agonist therapy5 7.
- Perceived weight discrimination significantly increases suicidal ideation risk in individuals with obesity13 14.
- Some GLP-1 users report mood changes, both positive and negative, highlighting the need for individualized monitoring18 .
- The history of psychiatric adverse events with some weight loss drugs has led to careful exclusion of patients with major psychiatric disorders from clinical trials of semaglutide19 .
- Further research is needed to clarify the impact of chronic diseases and their treatments on mental health outcomes5 7.
It is important for health professionals to assess, monitor, and treat mental health symptoms if they arise during treatment with these medications18 .
Managing Mental Health with Obesity and Diabetes Medications
Given the complex relationship between obesity, diabetes, and mental health, managing patients on GLP-1 receptor agonists requires careful attention to psychological well-being. While semaglutide appears safe and effective for most patients, including those with mental health concerns, individualized risk-benefit discussions with healthcare providers are essential5 7.
💡 Did You Know?
Semaglutide can be considered for patients with suicidal ideation who require treatment for diabetes or obesity, as current evidence does not support increased risk of suicidal thoughts with its use5 71.
Regular monitoring and open communication are important for patients using GLP-1R agonists, especially those with a history of depression, anxiety, or suicidal ideation5 710. Psychologists and behavioral health specialists play a vital role in supporting patients through the emotional and behavioral changes associated with weight loss and chronic disease management18 .
Challenges in managing mental health alongside obesity and diabetes medications include:
- Side effects such as nausea and gastrointestinal discomfort can impact mood and adherence18 .
- Weight loss can lead to shifts in body image, social relationships, and identity, which may require psychological support18 .
- Disparities in healthcare access may affect medication adherence and mental health outcomes among different racial and socioeconomic groups18 .
- Psychologists can help patients develop healthy relationships with food, manage disordered eating behaviors, and address anxiety or depression18 .
- Behavioral health interventions can enhance the overall effectiveness of GLP-1 therapies and improve quality of life18 .
